- Home
- BPMC
as 07-04-2025 9:42am EST
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 5.8B | IPO Year: | 2015 |
| Target Price: | $127.82 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $73.04 - $128.52 | Next Earning Date: | 07-31-2025 |
| Revenue: | $562,121,000 | Revenue Growth: | 99.19% |
| Revenue Growth (this year): | 44.46% | Revenue Growth (next year): | 32.78% |
Stock Insider Trading Activity of Blueprint Medicines Corporation (BPMC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carter Percy H. | BPMC | CHIEF SCIENTIFIC OFFICER | Jun 3 '25 | Sell | $127.88 | 2,659 | $340,032.92 | 56,624 | |
| Albers Jeffrey W. | BPMC | Director | May 27 '25 | Sell | $101.48 | 5,000 | $505,691.50 | 146,630 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | May 19 '25 | Sell | $100.84 | 2,274 | $228,557.31 | 64,718 | |
| Rossi Christina | BPMC | CHIEF OPERATING OFFICER | May 5 '25 | Sell | $102.28 | 2,274 | $231,386.14 | 64,718 | |
| Hurley Ariel | BPMC | PRINCIPAL ACCOUNTING OFFICER | May 5 '25 | Sell | $103.62 | 2,752 | $283,818.52 | 18,444 |
Latest Blueprint Medicines Corporation News
BPMC Breaking Stock News: Dive into BPMC Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Exploring US High Growth Tech Stocks For Potential Opportunities
Insider Monkey
11 days ago
Blueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic Mastocytosis
Simply Wall St.
12 days ago
Exploring 3 High Growth Tech Stocks In The US Market
Simply Wall St.
15 days ago
Exploring 3 High Growth Tech Stocks in the US Market
Simply Wall St.
16 days ago
Exploring Three High Growth Tech Stocks In The US Market
MT Newswires
18 days ago
Wells Fargo Downgrades Blueprint Medicines to Equalweight From Overweight, Price Target is $129
Simply Wall St.
18 days ago
Exploring High Growth Tech Opportunities in US Markets
PR Newswire
23 days ago
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
Compare BPMC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BPMC Blueprint Medicines Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.